Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 2;134(1):e177078.
doi: 10.1172/JCI177078.

Improving the safety of systemic viral gene therapy

Comment

Improving the safety of systemic viral gene therapy

Elizabeth M McNally. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: EMM has been or is a consultant to Amgen, AstraZeneca, Avidity Biosciences, Cytokinetics, 4D Molecular Therapeutics, Pfizer, and Tenaya Therapeutics. EMM is also a founder of Ikaika Therapeutics.

Comment on

References

    1. FDA. Approved Cellular and Gene Therapy Producsts. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... Updated June 30, 2023. Accessed November 6, 2023.
    1. Salabarria SM, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest. 2024;134(1):e173510. doi: 10.1172/JCI173510. - DOI - PMC - PubMed
    1. Lek A, et al. Meeting report: 2022 Muscular Dystrophy Association summit on ‘safety and challenges in gene transfer therapy’. J Neuromuscul Dis. 2023;10(3):327–336. doi: 10.3233/JND-221639. - DOI - PubMed
    1. Lek A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy. N Engl J Med. 2023;389(13):1203–1210. doi: 10.1056/NEJMoa2307798. - DOI - PMC - PubMed
    1. Bönnemann CG, et al. Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N Engl J Med. 2023;388(24):2294–2296. doi: 10.1056/NEJMc2212912. - DOI - PubMed

MeSH terms